Zoletorv – pharmacological profile

Česká verzia

Authors: B. Nussbaumerová
Authors place of work: Centrum preventivní kardiologie, II. interní klinika LF UK a FN, Plzeň
Published in the journal: Kardiol Rev Int Med 2017, 19(3): 201-204

Summary

Zoletorv, a new fixed-combination hypolipidaemic drug combining a modern and effective statin (atorvastatin) with a selective cholesterol absorption inhibitor (ezetimibe), has been marketed in the Czech Republic since September 2016. This fixed combination of two groups of hypolipidaemic drugs is more effective than statin monotherapy (dual inhibition principle). The IMPROVE-IT study has shown that the statin-ezetimibe combination significantly reduces the cardiovascular risk while being very well tolerated. The fixed combination of active substances contributes to an improved compliance with treatment.

Keywords:
atorvastatin – ezetimibe – fixed combination – hypolipidaemic treatment – cardiovascular risk

Zdroje

1. Catapano AL, Graham I, De Backer G et al. 2016 ESC/ EAS Guidelines for the management of dyslipidaemias. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2016; 37(39): 2999– 3058. doi: 10.1093/ eurheartj/ ehw272.

2. Kotseva K, Wood D, De Bacquer D et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic Ezetimibe/ atorvastatin in the management of hyperlipidemia 179 management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23(6): 636– 648. doi: 10.1177/ 2047487315569401.

3. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685– 696.

4. Amarenco P, Bogousslavsky J, Callahan A 3rd et al. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355(6): 549– 559.

5. Plakogiannis R, Cohen H, Taft D. Effects of morning versus evening administrationof atorvastatin in patients with hyperlipidemia. Am J Health Syst Pharm 2005; 62(23): 2491– 2494.

6. Souhrn údajů o přípravku Zoletorv. Dostupné na: http: / / www.msd.cz/ tinymce/ uploaded/ 20160527/ Zoletorv%2010%20mg-10%20mg_12.4.2016_SPC.pdf.

7. Sudhop T, Lutjohann D, Kodal A et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106(15): 1943– 1948.

8. Takase H, Dohi Y, Okado T et al. Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study. Eur J Clin Invest 2012; 42(12): 1287– 1294. doi: 10.1111/ eci.12000.

9. Yagi S, Akaike M, Aihara K et al. Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. J Atheroscler Thromb 2010; 17(2): 173– 180.

10. Pearson TA, Denke MA, McBride PE et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005; 80(5): 587– 595. doi: 10.4065/ 80.5.587.

11. Catapano A, Toth PP, Tomassini JE et al. The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. Clin Lipidol 2013; 8(1): 13– 41. doi: 10.2217/ clp.12.88.

12. Califf RM, Lokhnygina Y, Cannon PC et al. An update on the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J 2010; 159(5): 705– 709. doi: 10.1016/ j.ahj.2010.03.004.

13. Leiter LA, Bays H, Conard S et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 2008; 102(11): 1495– 1501. doi: 10.1016/ j.amjcard.2008.09.076.

14. Conard SE, Bays HE, Leiter LA et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 2008; 102(11): 1489– 1494. doi: 10.1016/ j.amjcard.2008.09.075.

15. Stein E, Stender S, Mata P et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004; 148(3): 447– 455. doi: 10.1016/ j.ahj.2004.03.052.

16. Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107(19): 2409– 2415. doi: 10.1161/ 01.CIR.0000068312.21969.C8.

17. Bays HE, Averna M, Majul C et al. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Am J Cardiol 2013; 112(12): 1885– 1895. doi: 10.1016/ j.amjcard.2013.08.031.

18. Tsujita K, Sugiyama S, Sumida H. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention. the multicenter randomized controlled PRECISE-IVUS Trial. J Am Coll Cardiol 2016; 66(5): 495– 507. doi.org/ 10.1016/ j.jacc.2015.05.065.